- Initial results expected 4Q 2025
SAN
DIEGO, Jan. 6, 2025 /PRNewswire/ -- Adcentrx
Therapeutics ("Adcentrx"), a clinical-stage biotechnology
company advancing innovative protein conjugates for cancer and
other life-threatening diseases, today announced the first patient
dosed in the Phase 1a/b study of ADRX-0405 for the treatment of
advanced solid tumors.
Adcentrx doses first patient in Phase 1a/b
study of ADRX-0405, a potential first-in-class STEAP1-targeting
ADC.
"Advancing our second program into clinical trials marks an
important milestone for Adcentrx and further validates the
potential of our ADC technology platform," said Hui Li, Ph.D., Founder and Chief Executive
Officer of Adcentrx. "STEAP1 is an attractive ADC target, and we
are excited about the first-in-class potential for ADRX-0405. We
believe this novel ADC offers a unique approach to treating
patients with STEAP1-expressing cancers, such as metastatic
castration-resistant prostate cancer, where a significant unmet
need remains for new targeted therapies."
The first-in-human Phase 1a/b clinical trial of ADRX-0405 is an
open-label dose escalation and dose expansion study being conducted
across sites in the U.S. The trial is enrolling patients with
select advanced solid tumors, with the primary objectives of
characterizing the safety and tolerability of ADRX-0405 and
determining its optimal dose. The company anticipates an initial
data readout in 4Q 2025.
About ADRX-0405
ADRX-0405 is a next-generation antibody-drug conjugate (ADC)
composed of a humanized IgG1 antibody targeting six-transmembrane
epithelial antigen of the prostate 1 (STEAP1), a cell surface
protein that is upregulated in prostate cancer and certain other
cancers, yet has limited expression in normal healthy tissue.
Adcentrx's proprietary i-Conjugation® technology platform is an
important component in the design of ADRX-0405. The platform
utilizes protease-cleavable linkers and stable conjugation
chemistry to enhance payload delivery. This advanced technology
ensures a highly stable ADC with a topoisomerase inhibitor payload
conjugated at a drug-to-antibody ratio of eight (DAR 8). ADRX-0405
preclinical studies have demonstrated its favorable
pharmacokinetics, safety profile, and significant efficacy across
multiple tumor models.
For more information about the ADRX-0405 Phase 1a/b clinical
trial, please refer to the Study ID NCT06710379 on
ClinicalTrials.gov.
About Adcentrx Therapeutics
Adcentrx is a biotechnology company focused on accelerating
breakthroughs in protein conjugate therapeutic development for
cancer and other life-threatening diseases. Adcentrx has pioneered
the development of i-Conjugation®, an ADC technology platform
addressing key components of protein conjugate design to solve
challenges typically seen in ADCs. In addition to ADRX-0405,
Adcentrx is developing a robust pipeline of ADCs with
first-in-class and best-in-class potential, including ADRX-0706, a
Nectin-4 targeting ADC currently in a Phase 1a/b clinical trial
(Study ID NCT06036121 on ClinicalTrials.gov).
For more information about Adcentrx and its innovative ADC
technologies, please visit https://adcentrx.com.
Contact Information:
Investor Relations
ir@adcentrx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/adcentrx-therapeutics-announces-first-patient-dosed-in-the-phase-1ab-study-of-adrx-0405-a-potential-first-in-class-adc-targeting-steap1-for-the-treatment-of-advanced-solid-tumors-302342200.html
SOURCE Adcentrx Therapeutics
